emjreviews.com1d
Neoadjuvant T-VEC Shows Promise for Difficult-to-Treat Basal Cell Carcinoma
T-VEC enables BCC resectability in 50% of cases, showing promise as a neoadjuvant therapy with mild side effects.
University of California1d
Breast cancer treatment advances with light-activated ‘smart bomb’
It is a useful therapy with several drawbacks that limit its effectiveness, including prolonged light sensitivity, poor ...
Science Daily29d
The proteins that make cell-to-cell cargo transport possible
The proteins that make cell-to-cell cargo transport possible. ScienceDaily . Retrieved February 12, 2025 from www.sciencedaily.com / releases / 2025 / 01 / 250115165210.htm ...